NCT06541028 Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)
| NCT ID | NCT06541028 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Hiv |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 135 participants in total. It began in 2025-11-04 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to develop an RS-ART implementation strategy by utilizing the Delphi method and interviewing experts and PWID regarding their experiences with ART. This strategy will then be pilot tested in a randomized controlled trial (Aim 3). The research will not impact the type of medication and dose prescribed, but rather, how soon providers are able to prescribe ART after diagnosis. The focus of this registration is Aim 3.
Eligibility Criteria
Inclusion Criteria: PWID in general population: * Be a PWID from the general population enrolling into ART services at one of the study's HIV clinics. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD). * Provide informed consent. * HIV clinicians prescribing ART 1. Be the HIV clinician who prescribes ART for a PWID in one of the selected clinics. 2. Be willing to use the RS-ART protocol. 3. Be at least 18 years old. No minors below age 18 will be enrolled in the study. 4. Provide informed consent. PWID in prison population: * Be a PWID enrolling into ART services at Kajang prison. PWID can include patients injecting opioids, amphetamines, or other combinations of injectable drugs. Some of these patients may be diagnosed with Opioid Use Disorder (OUD). * Provide informed consent. Exclusion Criteria: \-
Contact & Investigator
Frederick L Altice, MD
PRINCIPAL INVESTIGATOR
Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases)
Frequently Asked Questions
Who can join the NCT06541028 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hiv. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06541028 currently recruiting?
Yes, NCT06541028 is actively recruiting participants. Contact the research team at david.oliveros@yale.edu for enrollment information.
Where is the NCT06541028 trial being conducted?
This trial is being conducted at Kajang, Malaysia, Kuala Lumpur, Malaysia, Kuala Lumpur, Malaysia.
Who is sponsoring the NCT06541028 clinical trial?
NCT06541028 is sponsored by Yale University. The principal investigator is Frederick L Altice, MD at Professor of Medicine (Infectious Diseases) and of Epidemiology (Microbial Diseases). The trial plans to enroll 135 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.